|
1
|
Alghamdi IG, Hussain II, Alghamdi MS and
El-Sheemy MA: The incidence rate of female breast cancer in Saudi
Arabia: An observational descriptive epidemiological analysis of
data from Saudi Cancer Registry 2001–2008. Breast Cancer (Dove Med
Press). 5:103–109. 2013.PubMed/NCBI
|
|
2
|
Al-Rikabi A and Husain S: Increasing
prevalence of breast cancer among Saudi patients attending a
tertiary referral hospital: A retrospective epidemiologic study.
Croat Med J. 53:239–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijin M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:pp. 10869–10874. 2001; View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ades F, Zardavas D, Bozovic-Spasojevic I,
Pugliano L, Fumagalli D, De Azambuja E, Viale G, Sotiriou C and
Piccart M: Luminal B breast cancer: Molecular characterization,
clinical management, and future perspectives. J Clin Oncol.
32:2794–2803. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prat A, Cheang MC, Martin M, Parker JS,
Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen
TO and Perou CM: Prognostic significance of progesterone
receptor-positive tumor cells within immunohistochemically defined
luminal a breast cancer. J Clin Oncol. 31:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ladoire S, Mignot G, Dabakuyo S, Amould L,
Apetoh L, Rébé C, Coudert B, Martin F, Bizollon MH, Vanoli A, et
al: In situ immune response after neoadjuvant chemotherapy for
breast cancer predicts survival. J Pathol. 224:389–400. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cleator S and Ashworth A: Molecular
profiling of breast cancer: Clinical implications. Br J Cancer.
90:1120–1124. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bear HD, Anderson S, Brown A, Smith R,
Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham
DL and Wolmark N: National Surgical Adjuvant Breast and Bowel
Project Protocol B-27. The effect on tumor response of adding
sequential preoperative docetaxel to preoperative doxorubicin and
cyclophosphamide: Preliminary results from national surgical
adjuvant breast and bowel project protocol B-27. J Clin Oncol.
21:4165–4174. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mauri D, Pavlidis N and Ioannidis JP:
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A
meta-analysis. J Natl Cancer Inst. 97:188–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chollet P, Amat S, Cure H, De Latour M, Le
Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J and
Penault-Llorca F: Prognostic significance of a complete
pathological response after induction chemotherapy in operable
breast cancer. Br J Cancer. 86:1041–1046. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH,
Lee HE, Kim YJ, Kim JH and Park SY: Tumour-infiltrating CD8
lymphocytes as an independent predictive factor for pathological
complete response to primary systemic therapy in breast cancer. Br
J Cancer. 109:2705–2713. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Smyth MJ, Dunn GP and Schreiber RD: Cancer
immunosurveillance and immunoediting: The roles of immunity in
suppressing tumor development and shaping tumor immunogenicity. Adv
Immunol. 90:1–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boon T, Cerottini JC, Van den Eynde B, van
der Bruggen P and Van Pel A: Tumor antigens recognized by T
lymphocytes. Annu Rev Immunol. 12:337–365. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Melichar B, Študentova H, Kalábová H,
Vitásková D, Čermáková P, Hornychová H and Ryška A: Predictive and
Prognostic significance of tumor-infiltrating lymphocytes in
patients with breast cancer treated with neoadjuvant systemic
therapy. Anticancer Res. 34:1115–1125. 2014.PubMed/NCBI
|
|
16
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: From immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Denkert C, Loibl S, Noske A, Roller M,
Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R,
Hanusch C, et al: Tumor-associated lymphocytes as an independent
predictor of response to neoadjuvant chemotherapy in breast cancer.
J Clin Oncol. 28:105–113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee HJ, Seo JY, Ahn JH, Ahn SH and Gong G:
Tumor-associated lymphocytes predict response to neoadjuvant
chemotherapy in breast cancer patients. J Breast Cancer. 16:32–39.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ladoire S, Arnould L, Apetoh L, Coudert B,
Martin F, Chauffert B, Fumoleau P and Ghiringhelli F: Pathologic
complete response to neoadjuvant chemotherapy of breast carcinoma
is associated with the disappearance of tumor-infiltrating foxp3+
regulatory T cells. Clin Cancer Res. 14:2413–2420. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Houssami N, Macaskill P, von Minckwitz G,
Marinovich ML and Mamounas E: Meta-analysis of the association of
breast cancer subtype and pathologic complete response to
neoadjuvant chemotherapy. Eur J Cancer. 48:3342–3354. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nabholtz JM, Abrial C, Mouret-Reynier MA,
Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L,
Petit T, et al: Multicentric neoadjuvant phase II study of
panitumumab combined with an anthracycline/taxane based
chemotherapy in operable triple negative breast cancer:
Identification of biologically-defined signatures predicting
treatment impact. Ann Oncol. 25:1570–1577. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee AH, Gillett CE, Ryder K, Fentiman IS,
Miles DW and Millis RR: Different patterns of inflammation and
prognosis in invasive carcinoma of the breast. Histopathology.
48:692–701. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mahmoud SM, Paish EC, Powe DG, Macmillan
RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-Infiltrating
CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin
Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu S, Lachapelle J, Leung S, Gao D,
Foulkes WD and Nielsen TO: CD8+ lymphocyte infiltration is an
independent favorable prognostic indicator in basal-like breast
cancer. Breast Cancer Res. 14:R482012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ali HR, Provenzano E, Dawson SJ, Blows FM,
Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, et al:
Association between CD8+ T-cell infiltration and breast cancer
survival in 12,439 patients. Ann Oncol. 25:1536–1543. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matkowski R, Gisterek I, Halon A, Lacko A,
Szewczyk K, Staszek U, Pudelko M, Szynglarewicz B, Szelachowska J,
Zolnierek A and Kornafel J: The prognostic role of
tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer.
Anticancer Res. 29:2445–2451. 2009.PubMed/NCBI
|
|
27
|
Carlomagno C, Perrone F, Lauria R, De
Laurentiis M, Gallo C, Morabito A, Pettinato G, Panico L, Bellelli
T, Apicella A, et al: Prognostic significance of necrosis,
elastosis, fibrosis and inflammatory cell reaction in operable
breast cancer. Oncology. 52:272–277. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aaltomaa S, Lipponen P, Eskelinen M, Kosma
VM, Marin S, Alhava E and Syrjänen K: Lymphocyte infiltrates as a
prognostic variable in female breast cancer. Eur J Cancer.
28A:859–864. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sato E, Olson SH, Ahn J, Bundy B,
Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone
C, et al: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a
high CD8+/regulatory T cell ratio are associated with favorable
prognosis in ovarian cancer. Proc Natl Acad Sci USA. 102:pp.
18538–18543. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nakano O, Sato M, Naito Y, Suzuki K,
Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H and Ohtani H:
Proliferative activity of intratumoral CD8(+) T-lymphocytes as a
prognostic factor in human renal cell carcinoma: Clinicopathologic
demonstration of antitumor immunity. Cancer Res. 61:5132–5136.
2001.PubMed/NCBI
|
|
31
|
Kawai O, Ishii G, Kubota K, Murata Y,
Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, et al:
Predominant infiltration of macrophages and CD8(+) T cells in
cancer nests is a significant predictor of survival in stage IV
nonsmall cell lung cancer. Cancer. 113:1387–1395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fukunaga A, Miyamoto M, Cho Y, Murakami S,
Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y,
et al: CD8+ tumor-infiltrating lymphocytes together with CD4+
tumor-infiltrating lymphocytes and dendritic cells improve the
prognosis of patients with pancreatic adenocarcinoma. Pancreas.
28:e26–e31. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Camp BJ, Dyhrman ST, Memoli VA, Mott LA
and Barth RJ Jr: In situ cytokine production by breast cancer
tumor-infiltrating lymphocytes. Ann Surg Oncol. 3:176–184. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Muraro E, Martorelli D, Turchet E, Miolo
G, Scalone S, Comaro E, Talamini R, Mastorci K, Lombardi D, Perin
T, et al: A different immunologic profile characterizes patients
with HER 2-overexpressing and HER 2-negative locally advanced
breast cancer: Implications for immune-based therapies. Breast
Cancer Res. 13:R1172011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH
and van de Vijver MJ: WHO classification of tumors of the breast.
4. 4th. Lyon: International Agency for Research on Cancer; 2012
|
|
36
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging Manual. 7th. New York:
Springer; 2010
|
|
37
|
Ellis IO, Galea M, Broughton N, Locker A,
Blamey RW and Elston CW: Pathological prognostic factors in breast
cancer: II. Histological type. relationship with survival in a
large study with long-term follow-up. Histopathology. 20:479–489.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Elston CW and Elli IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. Histopathology. 41:151–153. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schnitt SJ: Classification and prognosis
of invasive breast cancer: From morphology to molecular taxonomy.
Mod Pathol. 23 Suppl 2:S60–S64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
West NR, Milne K, Truong PT, Macpherson N,
Nelson BH and Watson PH: Tumor-infiltrating lymphocytes predict
response to anthracycline-based chemotherapy in estrogen
receptor-negative breast cancer. Breast Cancer Res. 13:R1262011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mao Y, Qu Q, Zhang Y, Liu J, Chen X and
Shen K: The value of tumor infiltrating lymphocytes (TILS) for
predicting response to neoadjuvant chemotherapy in breast cancer: A
systematic review and meta-analysis. PLoS One. 9:e1151032014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Demaria S, Volm MD, Shapiro RL, Yee HT,
Oratz R, Formenti SC, Muggia F and Symmans WF: Development of
tumor-infiltrating lymphocytes in breast cancer after neoadjuvant
paclitaxel chemotherapy. Clin Cancer Res. 7:3025–3030.
2001.PubMed/NCBI
|
|
43
|
Ruffell B, Au A, Rugo HS, Esserman LJ,
Hwang ES and Coussens LM: Leukocyte composition of human breast
cancer. Proc Natl Acad Sci USA. 109:pp. 2796–2801. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Berke G: The binding and lysis of target
cells by cytotoxic lymphocytes: Molecular and cellular aspects.
Annu Rev Immunol. 12:735–773. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zitvogel L, Kepp O and Kroemer G: Immune
parameters affecting the efficacy of chemotherapeutic regimens. Nat
Rev Clin Oncol. 8:151–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shimizu J, Yamazaki S and Sakaguchi S:
Induction of tumor immunity by removing CD25+CD4+ T cells: A common
basis between tumor immunity and autoimmunity. J Immunol.
163:5211–5218. 1999.PubMed/NCBI
|
|
47
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Baker K, Lachapelle J, Zlobec I, Bismar
TA, Terracciano L and Foulkes WD: Prognostic significance of CD8+ T
lymphocytes in breast cancer depends upon both oestrogen receptor
status and histological grade. Histopathology. 58:1107–1116.
2011.PubMed/NCBI
|
|
49
|
Lee SM and Chow LQ: A new addition to the
PD-1 checkpoint inhibitors for non-small cell lung cancer-the
anti-PDL1 antibody-MED14736. Transl Lung Cancer Res. 3:408–410.
2014.PubMed/NCBI
|
